MedTrace Logo

Study of ALS Reversals 2: Genetic Analyses

NCT03464903 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 26

Last updated 2024-01-11

No results posted yet for this study

Summary

The purpose of this study is to try to understand why reversals of amyotrophic lateral sclerosis (ALS) and primary muscular atrophy (PMA) take place. The study will enroll patients with ALS or PMA reversals to give saliva samples in order to determine if the ALS or PMA reversal is because of certain changes in the genetic code.

Conditions

Sponsors & Collaborators

  • CReATe Consortium (funded by NIH/NCATS/NINDS)

    collaborator UNKNOWN

  • Duke University

    lead OTHER

Principal Investigators

  • Richard S Bedlack, MD, PhD · Duke Health

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-22
Primary Completion
2023-12-01
Completion
2023-12-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03464903 on ClinicalTrials.gov